Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 11;10(3):e003533. doi: 10.1136/jitc-2021-003533

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Vaccine injection schema of participants on the Mel48, Mel58, Mel60, and Mel63 clinical trials. Participants with resected stage II–IV melanoma were immunized with a combination of IFA alone, IFA + peptide, or IFA + pICLC + peptide. The peptides included one of MELITAC12.1, 6MHP, or LPV7. Participants underwent either rotating or same-site injection of the vaccine at three time points (weeks 0,1, 2). Tissue from the vaccine site was obtained by either punch biopsy or surgical excision 1 week after the first injection (week 1) and/or 1 week after the third injection (week 3). IFA, incomplete Freund’s adjuvant; pICLC, polyICLC; RV, rotating vaccines; SSV, same-site vaccination.